Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
British Journal of Dermatology · 20.06.2025 · 193 (1) · 44-55
DOI: 10.1093/bjd/ljaf032 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Dermatology, online erschienen am 25.01.2025. Verfasst von Richard B Warren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Manchester Biomedical Research Centre.
Abstract (Originalsprache)
Background
Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody that targets both IL-17A and IL-17F. BE RADIANT was the first phase III trial to investigate switching from selective inhibition of IL-17A to dual inhibition of IL-17A and IL-17F. Bimekizumab has previously shown superior achievement of complete skin clearance [100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100)] vs. secukinumab through 48 weeks. Switching from secukinumab to bimekizumab resulted in improved clinical responses. Over 2 years, no new safety signals were observed.
Objectives
To report the 3-year efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis receiving continuous bimekizumab or switching from secukinumab after 1 year.
Methods
The BE RADIANT phase IIIb randomized controlled trial had a 48-week double-blinded period, in which patients received bimekizumab [320 mg every 4 weeks (Q4W)] or secukinumab (300 mg weekly to week 4, then Q4W). At week 16, patients randomized to bimekizumab underwent re-randomization to receive Q4W or Q8W maintenance dosing. From week 48 onward (open-label extension), all received bimekizumab.
Results
In total, 336 patients randomized to bimekizumab and 318 randomized to secukinumab at baseline entered the open-label extension. More patients randomized to bimekizumab achieved PASI 100 (modified nonresponder imputation) at year 1 (74.9%) vs. those randomized to secukinumab (52.8%). PASI 100 response rates were maintained over 3 years in patients treated with bimekizumab (68.8%) and increased in those randomized to secukinumab switching to bimekizumab (68.8%). Bimekizumab was well tolerated to 3 years. In patients who received ≥ 1 bimekizumab dose, the most common treatment-emergent adverse events (TEAEs) over 3 years were nasopharyngitis, oral candidiasis and upper respiratory tract infection (exposure-adjusted incidence rates 12.2, 10.0 and 5.5/100 patient-years, respectively). Rates of TEAEs of interest, including serious infections, inflammatory bowel disease, and suicidal ideation and behaviour, did not increase with longer exposure to bimekizumab from 1 to 3 years.
Conclusions
More than two-thirds of patients randomized to bimekizumab and those who switched from secukinumab to bimekizumab achieved and maintained complete skin clearance over 3 years of treatment. Over 3 years, bimekizumab was well tolerated and TEAE rates did not increase with longer exposure.
Trial registration
NCT03536884
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
- Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
- SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada.
- Queen's University, Kingston, ON, Canada.
ORCID-Profile: Richard B Warren, Diamant Thaçi, Melinda Gooderham, Carle Paul, Bruce Strober
Förderung
- NIHR Manchester Biomedical Research Centre
Zitieren
APA
Warren, R. B., Lebwohl, M., Thaçi, D., Gooderham, M., Pinter, A., Paul, C., Gisondi, P., Szilagyi, B., White, K., Deherder, D., Staelens, F., Lambert, J., & Strober, B. (2025). Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal of Dermatology, 193(1), 44-55. https://doi.org/10.1093/bjd/ljaf032
Vancouver
Warren RB, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, et al. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal of Dermatology. 2025;193(1):44-55. doi:10.1093/bjd/ljaf032
BibTeX
@article{Warren2025,
author = {Warren, Richard B and Lebwohl, Mark and Thaçi, Diamant and Gooderham, Melinda and Pinter, Andreas and Paul, Carle and Gisondi, Paolo and Szilagyi, Balint and White, Katy and Deherder, Delphine and Staelens, Fabienne and Lambert, Jérémy and Strober, Bruce},
title = {Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period},
journal = {British Journal of Dermatology},
year = {2025},
volume = {193},
number = {1},
pages = {44--55},
doi = {10.1093/bjd/ljaf032}
}
EUVIMED